SarilumabNeutropenia following off-label use: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1921卷 / 1期

关键词：

D O I：

10.1007/s40278-022-22249-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：255 / 255

相关论文

共 50 条

[1] ClozapineAgranulocytosis following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1924 (1) : 164 - 164
[2] BebtelovimabAnaphylaxis following off-label use: 2 case reports
[J]. Reactions Weekly, 2023, 1954 (1) : 113 - 113
[3] FerumoxytolNausea following off-label use: 2 case reports
[J]. Reactions Weekly, 2017, 1650 (1) : 142 - 142
[4] UstekinumabMyositis following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1870 (1) : 306 - 306
[5] BevacizumabEndophthalmitis following off-label use: 2 case reports
[J]. Reactions Weekly, 2019, 1757 (1) : 64 - 64
[6] SorafenibLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2023, 1940 (1) : 384 - 384
[7] DaratumumabLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1925 (1) : 204 - 204
[8] AcetazolamideWorsening acidosis following an off-label use: 2 case reports
[J]. Reactions Weekly, 2020, 1821 (1) : 14 - 14
[9] TriamcinoloneOcular hypertension following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1917 (1) : 567 - 567
[10] OctreotideLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1859 (1) : 288 - 288

← 1 2 3 4 5 →